These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26082665)

  • 1. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.
    Shah AD; Shoback D; Lewiecki EM
    Int J Womens Health; 2015; 7():565-80. PubMed ID: 26082665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of romosozumab and its potential in the management of osteoporosis.
    Lim SY; Bolster MB
    Drug Des Devel Ther; 2017; 11():1221-1231. PubMed ID: 28458516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
    Marini F; Giusti F; Palmini G; Brandi ML
    Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis Treatment with Anti-Sclerostin Antibodies-Mechanisms of Action and Clinical Application.
    Rauner M; Taipaleenmäki H; Tsourdi E; Winter EM
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.
    McClung MR
    Ther Adv Musculoskelet Dis; 2017 Oct; 9(10):263-270. PubMed ID: 28974988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.
    Reid IR
    BioDrugs; 2017 Aug; 31(4):289-297. PubMed ID: 28547661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl K
    Wien Med Wochenschr; 2020 Apr; 170(5-6):124-131. PubMed ID: 31858345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases.
    Fabre S; Funck-Brentano T; Cohen-Solal M
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33114755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.
    Lim SY
    Womens Health (Lond); 2022; 18():17455057221125577. PubMed ID: 36154750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis.
    Aditya S; Rattan A
    J Midlife Health; 2021; 12(4):267-275. PubMed ID: 35264832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin Inhibition in the Management of Osteoporosis.
    Appelman-Dijkstra NM; Papapoulos SE
    Calcif Tissue Int; 2016 Apr; 98(4):370-80. PubMed ID: 27016922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
    Costa AG; Bilezikian JP; Lewiecki EM
    Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sclerostin antibodies in animal models of osteoporosis.
    Ominsky MS; Boyce RW; Li X; Ke HZ
    Bone; 2017 Mar; 96():63-75. PubMed ID: 27789417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.
    Lewiecki EM
    Ther Adv Musculoskelet Dis; 2014 Apr; 6(2):48-57. PubMed ID: 24688605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacology of bone anabolic agents].
    Matsumoto T
    Nihon Rinsho; 2015 Oct; 73(10):1639-44. PubMed ID: 26529924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.